Introduction

On April 2, 2026 – exactly one year after “Liberation Day” tariffs – President Trump signed two presidential proclamations that significantly reshape the tariff landscape for US imports. The first overhauls Section 232 tariffs on steel, aluminium, and copper, applying a 50% duty to the full entered value of these metals. The second imposes 100% tariffs on patented pharmaceutical products, with a complex system of exemptions for companies that sign onshoring and pricing agreements with the US government.

Both measures are framed as national security actions aimed at reducing US dependence on foreign supply chains and accelerating domestic manufacturing, the former being the legal reasoning behind Section 232. Together, they represent one of the most consequential tariff events of this cycle, with implications stretching far beyond the directly affected industries.

For investors, the new wave creates winners and losers across dozens of sectors, from construction and automotive to branded drug manufacturers and domestic metal producers. The impact is also amplified by the broader geopolitical context, with supply chains already stressed by the recent Strait of Hormuz crisis that sent global aluminium prices to record highs and disrupted pharmaceutical ingredient flows.

This article breaks down what changed on April 2, which sectors are most exposed, and what investors should be watching in the months ahead.

 

What Changed on April 2: The Section 232 Overhaul

Section 232 of the Trade Expansion Act of 1962 gives the President authority to impose tariffs on imports that threaten US national security. It is the same legal framework that underpinned earlier rounds of tariffs on steel and aluminium during the first Trump administration. The April 2026 proclamations use this authority to significantly expand both the scope and the rate of these tariffs.

The most important change is how the tariffs are calculated. Previously, Section 232 tariffs applied only to the metal content of an imported product. A steel beam incurred the tariff on its steel value, but a washing machine containing steel components paid tariffs only on the embedded metal, not the full product value. The new rules change this. As of April 6, 2026, the tariffs apply to the full customs value of finished products that contain significant amounts of steel, aluminium, or copper. This is a substantial expansion in practice, even without a change in the headline rate.

The pharmaceutical proclamation, signed the same day, opens an entirely new front in Section 232 tariff policy. This is the first time pharmaceuticals have been classified as a national security concern serious enough to trigger Section 232 measures, and the 100% headline rate is the highest applied under this authority.

Together, the two proclamations are affecting an estimated $400 billion in already-committed onshoring investment from US and foreign pharmaceutical companies alone.

 

Steel, Aluminium, and Copper: The 50% Hammer

The metals tariffs are structured in two tiers. Products made entirely or almost entirely of steel, aluminium, or copper, including unwrought metals, bars, rods, plates, sheets, tubes, and pipes, face a 50% tariff on the full entered value. Derivative products, meaning items that contain significant metal content but are not purely metal, face a 25% tariff on the full value, with an exemption for products where the metal content is less than 15% of total weight.

The rate increases alone are significant, but the shift to full-value taxation is transformational. Industry analysts have described it as moving the tariff system from a “carve-out model” to a “penalty-on-the-whole-invoice model.” A refrigerator, a car, a prefabricated building module, all now carry tariff exposure on their total value if they cross the metal content threshold.

The market impact has been immediate. Producer price indexes for aluminium mill shapes jumped 33% year-on-year and steel mill products rose 20.7%, the largest annual increases since the supply chain disruptions of early 2022. Construction input prices surged at an annualised rate of 12.6% in early 2026, the fastest pace since 2022. According to Brookings Institution estimates, the metals tariffs could add up to $30 billion to US housing costs, roughly $17,500 per new home built.

The copper tariff is particularly noteworthy because copper is critical to almost everything related to the energy transition, from electric vehicles to grid infrastructure to renewable energy systems. Higher copper prices add another headwind to an automotive sector already grappling with the costs of electrification and, before that, the aluminium supply shock from Gulf smelter damage during the Hormuz crisis.

 

Pharmaceuticals: The 100% Tariff and Its Loopholes

The pharmaceutical tariffs are arguably the more complex of the two proclamations. The headline rate is 100% on imported patented pharmaceuticals and their active ingredients, but the effective rate varies widely depending on company-specific agreements.

The structure works as follows. The default rate of 100% applies to imports from any country not explicitly granted preferential treatment. Only the EU, Japan, South Korea, Switzerland, Liechtenstein, and the UK are named in the preferential tier, where the rate is 15%. Companies that enter into onshoring agreements with the Department of Commerce, committing to build or expand US manufacturing, pay a 20% rate instead of 100%. This rate rises back to 100% on April 2, 2030, creating a four-year window for companies to complete their onshoring commitments.

The lowest tier applies to companies that sign pricing agreements with the Department of Health and Human Services under the administration’s Most Favoured Nation (MFN) drug pricing initiative. This policy borrows the term from trade agreements, where it refers to applying the best pricing available to any partner nation. Here, it commits companies to offering US customers prices no higher than those paid in other developed markets. In exchange, these companies receive a 0% tariff rate through January 20, 2029.

Generics and biosimilars, which account for over 90% of US prescriptions filled, are exempt for now, though the administration is required to reassess their status within one year.

For large branded drug manufacturers, the implementation timeline is tight. Tariffs take effect on July 31, 2026 for 17 named major companies, and on September 29, 2026 for all others. This gives companies roughly three to six months to finalise MFN agreements or onshoring plans, a compressed timeline by pharmaceutical industry standards.

 

Winners: Domestic Producers and Compliant Pharma

The most obvious beneficiaries of the April tariffs are US-based metal producers. Companies like Nucor, Steel Dynamics, Cleveland-Cliffs, and Alcoa gain significant pricing power as foreign competition becomes more expensive. US aluminium producers are also positioned to benefit from the structural shortage created by the combination of Hormuz-related supply disruptions and higher tariff barriers on imports.

Copper miners with significant US operations, including Freeport-McMoRan, are another clear winner. The 50% tariff on imported copper strengthens domestic pricing, and copper demand is structurally rising due to electrification and AI data centre buildouts.

On the pharmaceutical side, the winners are companies that have moved quickly to secure preferential tariff treatment. Pfizer, Eli Lilly, Bristol-Myers Squibb, and several other major US pharmaceutical companies have been among the first to negotiate MFN pricing agreements, qualifying for the 0% rate. Companies with substantial existing US manufacturing footprints, such as Johnson & Johnson and Merck, have structural advantages that smaller European and Asian competitors will struggle to replicate quickly.

The onshoring push also benefits US contract manufacturers, construction firms specialising in pharmaceutical facilities, and industrial real estate developers. Approximately $400 billion in new pharmaceutical investment has already been committed, much of which will flow through these supporting industries over the next several years.

Domestic construction firms focused on industrial and infrastructure projects, rather than residential, stand to benefit as reshoring accelerates. Companies building semiconductor fabs, pharmaceutical plants, and energy infrastructure have strong multi-year backlogs that should insulate them from the cost pressures affecting residential builders.

 

Losers: Construction, Automotive, and Branded Drug Importers

The losers are largely the industries that depend on the affected imports as inputs. US construction companies, particularly homebuilders, face immediate pressure. DR Horton, Lennar, PulteGroup, and similar names have to absorb or pass on higher material costs at a time when housing affordability is already strained. The $17,500 per-home cost increase estimated by Brookings is difficult to absorb given current margins.

The automotive sector is another major loser. Every passenger vehicle contains significant amounts of steel, aluminium, and copper. The shift to full-value taxation on derivative products particularly affects cars, which are high-value finished goods with substantial metal content. Detroit’s Big Three (Ford, GM, Stellantis) face higher input costs at a time when the industry is also investing heavily in electrification. Foreign automakers with US sales exposure, including Toyota, Hyundai, and Volkswagen, face additional pressure.

Consumer goods manufacturers are also exposed. Appliances, packaging, industrial equipment, and construction machinery all use substantial amounts of tariff-affected metals. Companies like Whirlpool, Caterpillar, and Deere face input cost pressures that will be difficult to fully pass through to end customers.

In pharmaceuticals, the losers are branded drug importers that have not secured MFN or onshoring agreements. European companies without significant US manufacturing footprints, particularly mid-tier pharmaceutical firms based in countries outside the preferential tier, face the full 100% tariff. Indian and Chinese pharmaceutical companies, major suppliers of active pharmaceutical ingredients, face significant disruption. CNBC has reported that Europe’s “pharma powerhouse era” may be drawing to a close as the combination of US tariffs, MFN pricing pressure, and Chinese biotech competition reshapes the industry.

The broader tariff landscape also creates challenges for retailers and consumers. Walmart, Target, and Amazon have all flagged input cost pressures in recent earnings guidance, much of which will eventually be passed to consumers in the form of higher prices.

 

The Onshoring Push: $400 Billion in New Investment

A key goal of the April tariffs is to accelerate the onshoring of critical manufacturing to the United States. In pharmaceuticals, this is already happening at scale. Approximately $400 billion in new investment commitments have been announced from US and foreign pharmaceutical companies, with construction of new facilities underway in states from North Carolina to Texas.

The US approach is distinctive in using tariff policy as a lever to force specific corporate commitments. The structure of the pharmaceutical tariffs, with differential rates based on onshoring plans and pricing agreements, is a relatively new tool in trade policy. It effectively allows the administration to negotiate with individual companies rather than purely country-to-country, reshaping how global corporations think about their US market access.

For investors, this creates opportunities in industrial real estate, construction, specialty chemicals, and industrial automation. Companies that supply the inputs and services needed to stand up new US manufacturing capacity are positioned for multi-year growth as the onshoring wave builds.

The critical minerals space is another major beneficiary. Trump’s recently launched $12 billion critical mineral reserve, “Project Vault,” is designed to reduce US dependence on Chinese-controlled mineral supply chains. Combined with the copper tariffs, this creates a strong investment case for US-focused mining and processing companies.

 

Inflation, Consumer Sentiment, and Central Bank Response

The tariffs arrive at a sensitive moment for the US economy. The Strait of Hormuz crisis has already pushed oil prices and input costs higher, creating inflationary pressures that had been easing prior to February. The April tariffs add another layer of price pressure across metals, pharmaceuticals, construction, automotive, and consumer goods.

US consumer sentiment hit a record low in April, with the University of Michigan index falling to 47.6, the lowest reading in the survey’s 74-year history. While not all of this can be attributed to tariffs, the combination of energy cost pressures from Hormuz, metal and pharma price pressures, a “jobless growth” paradigm, and general uncertainty has created a challenging environment for household budgets.

The IMF’s April 2026 World Economic Outlook revised global growth projections down, citing the combination of Middle East conflict, trade tensions, and tighter financial conditions. Global growth is now projected at 3.1% in 2026 and 3.2% in 2027, below prepandemic averages.

For central banks, the tariff-driven inflation creates the same dilemma as the energy-driven inflation from Hormuz. Tariffs raise prices but do not reflect demand strength, meaning monetary tightening cannot easily offset the inflationary effect. The Fed has held rates steady, with markets now pricing the next rate cut for mid-2027. The ECB is actually expected to raise rates one or two times before the end of 2026, a reversal from earlier expectations of cuts.

This has significant implications for rate-sensitive sectors. Real estate, consumer discretionary, and growth technology stocks face sustained headwinds if central bank easing is delayed further. Fixed-income portfolios, which had been positioning for rate cuts, may need to reassess duration exposure.

 

Sector Cascades: How the Tariffs Ripple

Like the Hormuz supply chain disruption, the April tariffs create cascading effects that extend well beyond the directly affected industries. Understanding these cascades is where investors can identify second-order opportunities.

Metals → Automotive → Dealers and Aftermarket. Higher steel, aluminium, and copper costs flow through to car manufacturers. Higher car prices affect new vehicle sales, which in turn affects auto dealers, finance companies, and aftermarket parts. But higher new vehicle prices also support used car values and benefit companies like CarMax and Carvana.

Metals → Construction → Housing → Home Improvement. Higher construction costs raise new home prices and reduce housing starts. This reduces demand for home appliances and furniture in new builds but increases demand for home improvement and remodelling as existing homeowners defer moves. Home Depot, Lowe’s, and specialty retailers benefit.

Metals → Industrial Equipment → Reshoring Infrastructure. Higher equipment costs increase the total cost of new US manufacturing facilities, but the onshoring mandate means that cost will be absorbed rather than avoided. Industrial automation, robotics, and engineering services companies see strong multi-year demand.

Pharma Tariffs → Drug Pricing → Healthcare Insurers. Higher branded drug costs will eventually flow through to US healthcare spending. Insurers like UnitedHealth and Elevance Health may face pressure on premiums and claims. Generic drug makers, exempt from the tariffs, gain market share as payers and patients seek alternatives.

Pharma Tariffs → Contract Manufacturing → Specialty Chemicals. The onshoring push creates demand for US contract development and manufacturing organisations (CDMOs), specialty chemical suppliers, and biotech infrastructure. Companies like Catalent, Thermo Fisher Scientific, and specialty chemicals firms are positioned to benefit.

These cascades show why sector-level analysis is critical when assessing the full impact of tariff policy changes.

 

What Investors Should Watch

Several variables will determine how the tariff environment evolves over the coming months:

  • MFN agreement uptake. The number of pharmaceutical companies signing MFN agreements to cap drug prices against foreign prices will shape the effective average tariff rate. Faster adoption means less inflationary impact but also less pressure for onshoring.
  • Onshoring execution. Announced investment commitments are promises, not construction. Watch for groundbreaking announcements, permits, and facility completions over the next 12 to 24 months as the real test of whether the tariff structure is driving meaningful manufacturing relocation.
  • Retaliatory tariffs. The EU, Japan, South Korea, and UK have preferential tariff tiers, reducing pressure for retaliation. But countries facing the default 100% rate have strong incentives to respond. Watch for targeted measures against US exports in agriculture, technology, or services.
  • Supply chain reconfiguration. Companies affected by the tariffs will pursue various strategies, including cost absorption, price increases, supplier diversification, and production relocation. Earnings guidance and capital expenditure plans will reveal how different sectors are adapting.
  • Consumer pass-through. The extent to which higher tariff costs are passed to consumers versus absorbed by companies will determine both the inflation impact and corporate margin trajectory. Watch consumer goods and healthcare companies for pricing guidance.
  • Legal challenges. Section 232 authority has been challenged before, and the expanded scope of the April tariffs may face fresh legal challenges. Any court rulings that constrain the tariff authority could meaningfully reshape the landscape.
  • Interaction with other trade agreements. The US has initiated or completed bilateral framework agreements with 18 countries and the EU. How these agreements evolve alongside the Section 232 tariffs will shape the broader trade picture. The EU-Mercosur agreement and other regional deals may take on new significance as companies look for ways to navigate the US tariff structure.

 

Sector Implications and DCSC

The April 2026 tariffs cut across some of the most fundamental sectors of the global economy, from metals and mining to pharmaceuticals, construction, automotive, and consumer goods. DCSC’s Dynamic Company Sector Classification system tracks over 1,500 sectors, giving investors the granularity to map their portfolio exposure against the specific industries and sub-industries affected by the new tariff regime.

Key sectors to explore include steel, aluminium, and copper (both producers and consumers), pharmaceuticals (branded and generic), construction and building materials, automotive manufacturing, contract manufacturing and specialty chemicals, industrial real estate, critical minerals and mining, and consumer goods. Understanding which companies are tariff-exposed, which are tariff-beneficiaries, and which sit in the middle of the supply chain is essential for navigating the current environment.

The tariff landscape will continue to evolve rapidly. Following the broader shift in trade relationships we’ve covered previously, the April 2026 measures represent another step in the restructuring of global trade and supply chains. Investors who can map their portfolios to the specific sectors most affected are best positioned to manage risk and identify opportunities.

Explore the full sector taxonomy at dcsc.ai, build a potential portfolio, or track the sector exposure of your current portfolio.